Nicotine is not a cigarette

Say the word nicotine and a hospital ward arrives with it. That reaction is not irrational and I have no interest in talking anyone out of it: cigarettes killed something on the order of a hundred million people in the twentieth century, and they are on course to kill more than that in this one. Any physician who is casual about tobacco has stopped paying attention.

But there is a cost to letting the reaction do all the thinking, and the cost is precision. If nicotine and cigarettes are one word in your mind, then you cannot reason about nicotine replacement therapy, you cannot read the Parkinson's epidemiology without either dismissing it or over-reading it, and — most practically — you cannot tell a patient which part of their habit is the part that is going to kill them.

So this is an exercise, and the subject is chosen for its difficulty. If the method on this site works here, it works.

Combustion. A burning cigarette is a small, dirty chemical reactor delivering tar, carbon monoxide, polycyclic aromatic hydrocarbons, tobacco-specific nitrosamines and a few thousand other compounds directly to alveolar tissue. That is the carcinogenic and cardiovascular load. Nicotine is the reason a person keeps returning to the reactor; the smoke is the reason the reactor is lethal.

This is not a contrarian position and it is not mine. It is the settled reading in tobacco control — the Royal College of Physicians put it plainly in 2016 — and it is the reason nicotine gum sits on an open pharmacy shelf while cigarettes sit behind a graphic warning. Regulators have separated these two things for decades. Ordinary conversation has not caught up.

Nicotine is a plant alkaloid, and its original job has nothing to do with us: it is an insecticide, which is why the plant makes it. In a mammal it acts as an agonist at nicotinic acetylcholine receptors — the same receptors acetylcholine uses — with the α4β2 subtype in the midbrain being the one that matters for dependence. Activation there increases dopamine release in the nucleus accumbens, which is the common final pathway of nearly every addictive drug.

The part most explanations skip is that the pharmacokinetics carry much of the addictive weight, not the molecule alone. Inhaled through the lung, nicotine reaches the brain in something like ten seconds — faster than an intravenous injection into an arm vein, because it takes the short route. That speed is what makes an inhaled dose reinforcing in a way the same amount absorbed slowly through the buccal mucosa or the skin simply is not. Same drug, different arrival, different behaviour.

Chronic exposure upregulates those receptors, which is the physical substrate of tolerance and of withdrawal. None of this is mysterious and none of it is benign: this is a description of how a dependence is built.

Nicotine is a stimulant with measurable acute cognitive effects in humans, including in people who have never smoked. A 2010 meta-analysis across dozens of controlled studies found reliable acute improvements in fine motor performance, attention and working memory. That is a real result in a real literature.

It is also precisely the result that gets over-read, and I want to name the over-reading before anyone else does it for me. Acute effects on a laboratory task are not a claim about a life. Caffeine improves the same measures, and nobody thinks that settles whether caffeine is good for you. What the finding does establish is narrower and more useful: nicotine is a psychoactive drug with genuine effects, not a mere impurity in smoke.

Smokers get Parkinson's disease less often. This is one of the most replicated inverse associations in neuroepidemiology — roughly half the incidence of never-smokers in pooled analyses — and it has survived decades of attempts to make it go away.

There are three serious explanations and they are not mutually exclusive. Nicotine may be genuinely neuroprotective to dopaminergic neurons. Other tobacco constituents inhibit monoamine oxidase B, which is itself a target of Parkinson's drugs. Or the arrow runs backwards: the prodromal phase of Parkinson's, which begins decades before diagnosis, involves reduced novelty-seeking, so people already on that path may simply take up smoking less often.

What has not happened is the obvious next step. Nicotine has been trialled as a therapy in Parkinson's and the results have been disappointing — a large randomised trial of transdermal nicotine failed to show benefit. So the honest position is: a robust association, three live hypotheses, and no therapy. This is where the longevity conversation runs well ahead of its evidence, and I mark it emerging rather than established for exactly that reason.

The general lesson is worth more than the specific case. An association this strong and this replicated still did not survive contact with a randomised trial. Anyone who tells you an epidemiological finding is a protocol has skipped the only step that matters.

Here is the strongest single argument for keeping the two things separate in your head. Tobacco smoke contains monoamine oxidase inhibitors — harman and norharman among them — and smokers show markedly reduced MAO-B activity in the brain compared with non-smokers. MAO inhibition potentiates dopaminergic signalling.

Which means the cigarette is not merely a nicotine delivery device. It is a nicotine delivery device plus an adjuvant that raises the addictive potential of the nicotine it delivers, arriving by the fastest possible route, in a product engineered over a century to optimise exactly that. Nicotine alone, absorbed slowly, is a considerably weaker hook than the thing people actually get addicted to. That difference is not a rounding error; it is most of the story.

Tobacco is not a Western invention and its first use was not recreational. Across Amazonia, Nicotiana rustica — a species carrying several times the nicotine of the N. tabacum in a commercial cigarette — has been used as a shamanic tool for a very long time: administered ritually, in specific forms, at doses that would be frankly toxic in any other context, by practitioners who trained for years to work with it. Johannes Wilbert's Tobacco and Shamanism in South America remains the standard documentation, and what it documents is a pharmacologically serious practice, not a habit.

I want to be careful about what that does and does not establish, because this is the tier where this site is most often misread. Traditional use is not evidence of safety. It is evidence of something else, and the something else is interesting: a relationship that was bounded, purposeful, and supervised. The plant was approached for a reason, on an occasion, under instruction, and then put down.

Set the modern cigarette beside that and the contrast is total. Unbounded, purposeless, unsupervised, and twenty times a day. Same genus, same alkaloid, opposite relationship — and it is the relationship, far more than the molecule, that determines what the thing does to a life. That is an observation, not a finding, and I offer it as one.

같은 식물, 전혀 다른 관계.

Plainly, and without hedging, because this is the part that matters clinically:

Nicotine is addictive. That is its primary harm and it is not a small one. Dependence costs money, attention and autonomy, and it is much easier to acquire than to be rid of. Nothing else in this essay outranks that sentence.

It is not cardiovascularly neutral. It acutely raises heart rate and blood pressure and causes vasoconstriction. Whether nicotine alone carries meaningful long-term cardiovascular risk in the absence of smoke is genuinely not settled — which means it is not established as harmful and equally not established as safe, and anyone claiming either is telling you more than the literature does.

Absolutely not in pregnancy, and not in adolescence. Fetal nicotine exposure has documented effects on neurodevelopment, and the adolescent brain is measurably more vulnerable to acquiring dependence. These are not cautious hedges; they are the two hard lines.

This is not a recommendation. I do not tell patients to take up nicotine and this essay is not a quiet way of doing so. There is no dose here, no product, and no protocol, and their absence is deliberate.

And if you do smoke: the most valuable single thing available to you is to stop the smoke. Nicotine replacement is a legitimate, licensed, pharmacy-shelf tool for that, and a person who switches has removed the part of their habit that causes the cancer and the emphysema. That is not a small win, and treating nicotine and cigarettes as one thing is what stops people from seeing it.

Hold two sentences at once. Nicotine is addictive and I do not recommend it. Nicotine is not the reason cigarettes kill people. Both are true, neither cancels the other, and the discomfort of holding them together is the whole exercise.

Most bad thinking about substances — and about practices, and about medicine — is a flinch away from that discomfort in one of two directions. Either the harm swallows the whole subject so that nothing can be examined, or the interesting finding swallows the harm so that nothing is cautioned. The discipline is to stay in the room with both.

That is the method, and nicotine is where I test it. If it holds here, you can trust it on breath, on energy, and on everything else this school teaches — and if it ever stops holding, you should stop trusting me.

References

1. Benowitz, N. L. (2010). Nicotine Addiction. New England Journal of Medicine, 362(24), 2295–2303.●The standard clinical review of the pharmacology, including why route of administration carries so much of the addictive weight.
2. Royal College of Physicians (2016). Nicotine without smoke: Tobacco harm reduction. London: RCP.●Where the separation of the drug from the smoke is argued at length by a body with no interest in selling either.
3. Fowler, J. S. et al. (1996). Inhibition of monoamine oxidase B in the brains of smokers. Nature, 382(6588), 622–625.●The MAO-B finding — the cigarette is more than its nicotine.
4. Heishman, S. J., Kleykamp, B. A. & Singleton, E. G. (2010). Meta-analysis of the acute effects of nicotine and smoking on human performance. Psychopharmacology, 210(4), 453–469.●The acute cognitive effects, including in non-smokers. Acute, and on laboratory tasks.
5. Hernán, M. A. et al. (2002). A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Annals of Neurology, 52(3), 276–284.●The inverse association, pooled.
6. Parkinson Study Group NIC-PD Investigators (2017). Nicotine for the treatment of Parkinson's disease: a randomized, double-blind, placebo-controlled trial. (NIC-PD)●The trial that did not show benefit — cited because the negative result is the point.
7. Benowitz, N. L. & Burbank, A. D. (2016). Cardiovascular toxicity of nicotine: Implications for electronic cigarette use. Trends in Cardiovascular Medicine, 26(6), 515–523.●The basis for the cardiovascular paragraph, and for declining to call nicotine alone either safe or established-harmful.
8. Bruin, J. E., Gerstein, H. C. & Holloway, A. C. (2010). Long-term consequences of fetal and neonatal nicotine exposure: a critical review. Toxicological Sciences, 116(2), 364–374.●Why pregnancy is a hard line rather than a caution.
9. Wilbert, J. (1987). Tobacco and Shamanism in South America. New Haven: Yale University Press.○The standard ethnographic documentation of ritual tobacco use, including Nicotiana rustica dosing.